Emerging Markets Earnings Roundup: Sanofi And GSK (Part 6)
This article was originally published in PharmAsia News
Emerging markets represent the biggest portion of Sanofi’s business, while GSK’s 10% growth in emerging markets for 2012 barely covered dismal European sales.
You may also be interested in...
GlaxoSmithKline will implement a new £1.5 billion restructuring program to improve commercial efficiencies in Europe and adopt new manufacturing processes, following sales and profits shortfalls in 2012.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.